Applications of D-2-Furylalanine in Industrial Manufacturing

D-2-Furylalanine serves as a specialty amino acid derivative. Its applications concentrate in pharmaceutical synthesis, advanced peptide research, chiral intermediate production, and high-end diagnostic reagents. As a direct manufacturer, we supply D-2-Furylalanine to established industrial partners whose downstream processes demand precise formulation, stringent quality control, and adherence to recognized global standards.

1. Pharmaceutical Peptide Synthesis

Peptide drug manufacturers use D-2-Furylalanine as a non-natural amino acid building block when constructing complex peptide APIs, including protease inhibitors, peptide receptor modulators, and custom peptide therapeutics. In this sector, strict enantiopurity and contaminant control are mandatory. Our production delivers material suitable for both regulatory submission batches and process scale-up, supporting consistent chain elongation and protecting key functional groups during solid-phase synthesis steps. Downstream partners achieve enhanced biochemical properties or modified activity in their finished APIs through precision introduction of this rare amino acid.

Industry compliance standards

• ICH Q7 GMP for APIs
• US FDA 21 CFR Part 210/211 for drug substance production
• Ph. Eur. and USP standards for identity and purity testing
• ICH Q3A/B guidelines for impurity profiles

Typical usage ratio

• 0.5–3% molar ratio within peptide chains; exact proportion defined by target sequence incorporation and peptide length.

Downstream process integration

• Direct Fmoc/Boc-protected integration during solid-phase peptide synthesis (SPPS)
• Pre-activation as ester for automated synthesizer applications
• Post-integration deprotection and chain extension workflows
• Final peptide purification by HPLC with D-2-Furylalanine incorporated

Final product types

• Peptide API candidates for injection or oral forms
• Chemically stabilized peptide analogues
• Modified peptides for targeted drug delivery systems
• Clinical development reference standards

2. Chiral Intermediate Manufacture for Small Molecule APIs

Several advanced small molecule developers employ D-2-Furylalanine as a chiral source for structural diversification and asymmetric synthesis. The material delivers a unique furan side chain while maintaining high enantiomeric excess. It enters as a nucleophilic or electrophilic precursor in key steps such as amide bond formation, chiral pool synthesis, and resolution of racemates, especially in heterocyclic or aromatic functionalized drug candidates. D-2-Furylalanine’s robust stereochemistry aids in patentable space creation and new API pipelines.

Industry compliance standards

• US FDA DMF submission requirements for intermediates
• ICH Q11 process validation for intermediates
• ISO 9001:2015 Quality Systems for chemical manufacturing
• REACH registration and safety documentation (EU)

Typical usage ratio

• 10–45% wt/wt relative to reaction batch size; varies by intermediate structure and downstream conversion yield.

Downstream process integration

• Initiation point for asymmetric amide coupling and hydrazinolysis
• Protective group strategies involving carboxyl and amino functionalities
• Enantiomeric enrichment for final API intermediate crystallization
• Multiple-stage batch and continuous processing lines

Final product types

• Chiral intermediates for antihypertensive and antineoplastic APIs
• Pesticide intermediate bases
• Diagnostic probe backbone compounds (small molecules)
• Advanced fine chemical blocks sold to contract manufacturers

3. Diagnostic Peptide and Immunoassay Reagent Development

In the diagnostics industry, D-2-Furylalanine enables site-specific labeling and structure modification of peptide antigens and immunoassay reagents. Its unique furan ring provides a functional handle for chemical conjugation, affording selective cross-linking and fluorescence tagging in ELISA kits and lateral flow assay components. We supply high-purity grades for direct use in custom reagent manufacturing, including lyophilized test kits and antibody-binding sequences used in certified laboratory settings.

Industry compliance standards

• ISO 13485:2016 for medical device and diagnostic reagent QC
• CE-IVD marker requirements for European market
• FDA 21 CFR 820 QSR for US diagnostics manufacturing
• Internal QC release requirements: purity, endotoxin, and sterility

Typical usage ratio

• 1–7% of peptide sequence positions; ratio determined by assay specificity, labeling density, and sensitivity requirements.

Downstream process integration

• Synthesis of peptide antigens carrying D-2-Furylalanine at defined loci
• Chemical activation for cross-linked reporter group coupling
• Assembly of ready-to-use diagnostic kit subcomponents (e.g., coated microplates, labeled detection probes)
• Freeze-drying and QC batch release for commercial test kits

Final product types

• ELISA antigens and controls
• Rapid diagnostic test strip reagents
• Automated immunoassay kit components
• Protein labeling reference standards

4. High-Purity Research and Development Supply for Chemical Biology

Leading chemical biology research teams and contract research organizations procure D-2-Furylalanine to support custom probe design, biosensor construction, and non-natural amino acid incorporation studies. Incorporation into recombinant expression systems or chemical ligation protocols allows for exploration of electron-rich aromatic side chains in enzyme mechanism research and protein engineering. We deliver lot-specific analytical reports, low-metal content, and strictly managed cold-chain or ambient bulk packaging options for global research partners.

Industry compliance standards

• Good Laboratory Practice (GLP) for research batch traceability
• ISO/IEC 17025 for analytical verification
• Certificate of Analysis (CoA) providing NMR, HPLC, and MS validation
• Custom documentation for academic and industrial grant compliance

Typical usage ratio

• Microgram to multigram scale; concentration per expression or assay typically 0.01–2 mM, adjusted per project protocol.

Downstream process integration

• Incorporation via auxotrophic cell line feeding or genetic code expansion systems
• Chemoselective modification in click chemistry workflows
• On-resin peptide ligation for mechanistic studies
• High-throughput screening of compound libraries containing D-2-Furylalanine

Final product types

• Protein structure-function research samples
• Site-modified enzyme analogues
• Biochemical assay probes with furan moieties
• Custom research peptides for publication-grade experiments